Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

ed from the hospital within 48 hours after the surgical procedure.

The primary outcome measure was the difference in UPDRS motor scores between NLX-P101 and sham-treated subjects, when the subjects were off PD medication. Other tests assessed motor fluctuations, constancy of medication effect and neuropsychological evaluations. A clinically-meaningful response was defined based on a 25 percent mean improvement from the initial Phase 1 NLX-P101 study (9 points). Patients in the sham surgery arm of the study who continue to meet all eligibility requirements will be provided an opportunity to receive NLX-P101 in a planned cross-over study. Treated subjects continue to be evaluated in an open-label, long-term follow-up study.

A Novel Approach to Gene Therapy

NLX-P101 aims to reset the overactive brain cells in the STN to inhibit electrical activity and return brain network activity to more normal levels. In PD, the loss of dopamine-secreting neurons alters chemical signaling pathways in the brain such that input to the STN is altered. The therapeutic approach with NLX-P101 modulates the activity of the STN (which is overactive in PD) by restoring GABA, a neurotransmitter important in STN function. GABA is made by a gene called glutamic acid decarboxylase (GAD). NLX-P101 uses an AAV vector (a disabled, non-pathogenic virus) to deliver the GAD gene into the STN. Increasing GAD activity causes more GABA to be synthesized, thus helping to lessen the STN over-activity.

About Parkinson's disease

Parkinson's disease is a progressive and debilitating neurodegenerative disorder that arises from the gradual deterioration of nerve cells in the brain. It affects the control of bodily movement and is characterized by four principal features: limb tremor, limb rigidity, bradykinesia (slowness of movement) and postural instability (trouble with balance).  

Parkinson's disease is typically a disease that affects people over
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 10 Eli Lilly and Company (NYSE: LLY ... the Second Circuit has agreed with Lilly,s position that a ... payor suit, in which unions and insurers who act as ... court also agreed with Lilly that plaintiffs, overpricing claims should ...
... (NYSE Amex: PTN ) announced that it will ... Conference / 12th Annual Healthcare Conference on Tuesday, September 14, ... September 12-15 at the New York Palace Hotel in New ... Chief Executive Officer of Palatin Technologies, will provide an update ...
Cached Medicine Technology:U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... 11 The Campaign for Tobacco-Free Kids applauds U.S. Senator ... the U.S. Food and Drug Administration (FDA) authority to regulate ... marketing and sales to kids. The U.S. Senate approved ... approved similar legislation, and Congress is expected to quickly send ...
... , WASHINGTON, June 11 The Campaign for Tobacco-Free Kids ... today to approve historic legislation that gives the U.S. Food ... the authority to crack down on tobacco marketing and sales ... 79 to 17. The House has approved similar legislation, ...
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Frank Lautenberg ... that gives the U.S. Food and Drug Administration (FDA) authority ... on tobacco marketing and sales to kids. The U.S. ... House has approved similar legislation, and Congress is expected to ...
... The Campaign for Tobacco-Free Kids applauds U.S. Senators Herb ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...
... JOURNEY , , Follow McCoy,s Trip at http://www.theunbeatentrack.com ... Travis McCoy, lead vocalist & songwriter of Gym Class Heroes ... Senior Vice President, Social Responsibility, MTV Networks International and Executive ... South Africa, the Philippines and India to raise awareness about ...
... statement of CEO Nancy Brown on the Senate passage of ... today by the American Heart Association: , , The ... ensure a healthier future for our children with passage of ... legislation will allow us to protect them from a dirty ...
Cached Medicine News:Health News:Senator Landrieu Votes to Protect America's Kids from Tobacco 2Health News:Senators Gregg and Shaheen Vote to Protect America's Kids From Tobacco 2Health News:Senators Lautenberg and Menendez Vote to Protect America's Kids from Tobacco 2Health News:Senators Kohl and Feingold Vote to Protect America's Kids From Tobacco 2Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 2Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 3Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 4Health News:Travis McCoy, Lead Vocalist & Songwriter of Alternative Hip Hop Band Gym Class Heroes, Travels to South Africa, Philippines and India as MTV International's 2009 Staying Alive Foundation Ambassador 5
Designed to meet the demands of today's laboratories for RO water....
... L/day of Type III Laboratory-grade Water, RiOs ... up to 8000 L/day of Type III ... Complete Purification and Control Unit, RiOs systems ... providing total control of all parameters within ...
... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
... Model U410 is an upright freezer ... our Innova line, but using conventional ... a cost-effective alternative. Similar in size ... 240 2" boxes. Includes five compartments ...
Medicine Products: